Clinical Nuclear Medicine · 2018 · 38 citations · 37 references
MedicineNuclear MedicineRadiologyEndocrine Nuclear MedicineEndocrine OncologyMolecular ImagingEndocrine ImagingEndocrine Tumor ImagingNeuroendocrine TumorsPositron Emission TomographySomatostatin Receptor ImagingTumor Imaging68Ga-dotatate ImagingGallium-68 Dotatate PetGallium-68 Dotatate Positron Emission TomographyGallium-68 LabelingGallium-68 RadiopharmaceuticalsSomatostatin Receptor TargetingWell-differentiated Neuroendocrine TumorsWell-differentiated Tumors
Radiopharmaceuticals targeting cell surface expression of somatostatin receptors (SSTRs) are particularly useful in the evaluation of neuroendocrine tumors. Gallium-68 DOTA-Tyr-octreotatate (Ga-DOTATATE) primarily binds to SSTR type 2 receptors. Ga DOTATATE PET/CT is proven to have high impact on the management of neuroendocrine patients compared to traditional anatomical imaging as well as provides additional information over that of conventional nuclear medicine studies (indium-III DTPA-octreotide). It can result in change in management of approximately 75% of patients with neuroendocrine tumors. Ga DOTATATE and F FDG PET/CT imaging are complementary, with the degree of uptake varying depending on the degree of differentiation of the tumor. Well-differentiated tumors maintain their SSTRs and are positive on Ga DOTATATE PET/CT scan, while dedifferentiated tumors are less likely to demonstrate uptake of Ga DOTATATE but will demonstrate uptake with F FDG PET/CT. In addition, Ga DOTATATE PET/CT identifies patients with SSTR expression in their tumors, who have progressed on somatostatin analog therapy, for treatment with Lu DOTATATE.
37
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text
Medicine, Oncology, Pharmacology +17
Jean Claude Reubi, Jean-Claude Schär, Beatrice Waser et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2000 · 1.1K citations